Trial Profile
A retrospective trial to study the efficacy and safety of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology